Keros Therapeutics (NASDAQ:KROS) Given New $25.00 Price Target at Truist Financial

Keros Therapeutics (NASDAQ:KROS) had its price objective dropped by stock analysts at Truist Financial from $43.00 to $25.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Truist Financial’s price target indicates a potential upside of 104.25% from the company’s current price.

Other equities research analysts also recently issued reports about the stock. Cantor Fitzgerald downgraded shares of Keros Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Tuesday, January 21st. Scotiabank cut their target price on Keros Therapeutics from $44.00 to $41.00 and set a “sector outperform” rating on the stock in a research report on Thursday, January 16th. Guggenheim restated a “neutral” rating on shares of Keros Therapeutics in a research report on Friday, January 17th. Piper Sandler dropped their price objective on Keros Therapeutics from $40.00 to $15.00 and set an “overweight” rating for the company in a research note on Friday, January 17th. Finally, Wells Fargo & Company decreased their target price on Keros Therapeutics from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, February 27th. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, Keros Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $40.33.

Keros Therapeutics Stock Up 18.5 %

KROS stock opened at $12.24 on Wednesday. Keros Therapeutics has a 52-week low of $9.12 and a 52-week high of $72.37. The stock has a market cap of $496.48 million, a price-to-earnings ratio of -2.35 and a beta of 1.39. The business has a fifty day moving average of $10.88 and a two-hundred day moving average of $31.11.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($1.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.36) by $0.22. The firm had revenue of $3.04 million during the quarter, compared to the consensus estimate of $37.32 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. As a group, sell-side analysts anticipate that Keros Therapeutics will post -4.74 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in KROS. Braidwell LP grew its position in shares of Keros Therapeutics by 167.9% in the 4th quarter. Braidwell LP now owns 1,894,439 shares of the company’s stock valued at $29,989,000 after buying an additional 1,187,199 shares during the last quarter. Lynx1 Capital Management LP purchased a new position in Keros Therapeutics during the fourth quarter worth about $8,612,000. Millennium Management LLC raised its stake in shares of Keros Therapeutics by 53.3% during the 4th quarter. Millennium Management LLC now owns 878,159 shares of the company’s stock worth $13,901,000 after buying an additional 305,169 shares in the last quarter. Boxer Capital Management LLC acquired a new stake in Keros Therapeutics in the fourth quarter valued at $3,958,000. Finally, Integral Health Asset Management LLC lifted its stake in shares of Keros Therapeutics by 125.0% in the fourth quarter. Integral Health Asset Management LLC now owns 450,000 shares of the company’s stock valued at $7,124,000 after purchasing an additional 250,000 shares during the period. 71.56% of the stock is owned by institutional investors and hedge funds.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.